Travaux scientifiques

Prof. Dr. Meral Beksaç

912 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Talquetamab–Daratumumab in Relapsed or Refractory Myeloma

    New England Journal of Medicine, 2026

    DOI 10.1056/nejmoa2604657 PMID 42294841 8 citations (Europe PMC) Source : OpenAlex

  2. POSTER: MM-593: Phase 3 Randomized Study of Talquetamab + Daratumumab ± Pomalidomide vs Daratumumab + Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: MonumenTAL-3

    Clinical Lymphoma Myeloma & Leukemia, 2026

    DOI 10.1016/s2152-2650(26)01331-5 Source : OpenAlex

  3. MM-593: Phase 3 Randomized Study of Talquetamab + Daratumumab ± Pomalidomide vs Daratumumab + Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: MonumenTAL-3

    Clinical Lymphoma Myeloma & Leukemia, 2026

    DOI 10.1016/s2152-2650(26)02897-1 Source : OpenAlex

  4. How to treat hepatic extra-medullary involvement of myeloma: a case report and review of literature

    Leukemia & lymphoma, 2026

    DOI 10.1080/10428194.2026.2715203 PMID 42604567 Source : Europe PMC

  5. 2026 Myeloma Treatment Guidelines of the Turkish Myeloma Study Group

    Clinical Lymphoma Myeloma and Leukemia, 2026

    DOI 10.1016/j.clml.2026.08.008 PMID 42705998 Source : ORCID

  6. Non-cryopreserved hematopoietic stem cell transplantation compared to conventional autologous peripheral stem cell transplantation with cryopreserved stem cells among patients newly diagnosed with myeloma

    Transfusion and Apheresis Science, 2026

    DOI 10.1016/j.transci.2026.104493 PMID 42462602 Texte intégral en libre accèsSource : ORCID

  7. [11C]-Methionine PET/CT in evaluation of bone marrow infiltration and usage as a prognostic tool in multiple myeloma

    Annals of Nuclear Medicine, 2026

    DOI 10.1007/s12149-026-02180-6 PMID 41739434 Source : ORCID

  8. Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco-25-00924 PMID 41370738 5 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  9. Daratumumab‐based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study

    HemaSphere, 2026

    DOI 10.1002/hem3.70287 PMID 41523083 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

  10. Non-cryopreserved Hematopoietic Stem Cell Transplantation compared to Conventional Autologous Peripheral Stem Cell Transplantation with cryopreserved stem cells improves engraftment. Results of a Single-Center Experience

    2026

    DOI 10.2139/ssrn.6758177 Source : ORCID

  11. 2025 Update of Cellular Immunotherapy for Plasma Cell Disorders

    Turkish journal of haematology : official journal of Turkish Society of Haematology, 2026

    DOI 10.4274/tjh.galenos.2025.2025.0330 PMID 41428622 Texte intégral en libre accèsSource : Europe PMC

  12. Innate immunogenetic synergy between KIR and Neanderthal-derived OAS variants predicts COVID-19 outcomes

    PloS one, 2026

    DOI 10.1371/journal.pone.0345137 PMID 42201890 Texte intégral en libre accèsSource : Europe PMC

  13. Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS

    Blood advances, 2026

    DOI 10.1182/bloodadvances.2026019937 PMID 42234958 Texte intégral en libre accèsSource : Europe PMC

  14. The cumulative effect of cytogenetic abnormalities on the outcomes of myeloma patients with del(17p) undergoing AHSCT in EBMT centres between 2016 and 2022

    British journal of haematology, 2026

    DOI 10.1111/bjh.70759 PMID 42618062 Texte intégral en libre accèsSource : Europe PMC

  15. Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026

    DOI 10.1200/jco-26-00401 PMID 42789828 Texte intégral en libre accèsSource : Europe PMC

  16. Daratumumab-bortezomib-cyclophosphamide-dexamethasone for newly diagnosed amyloidosis: ANDROMEDA final survival analysis

    Blood, 2026

    DOI 10.1182/blood.2025032099 PMID 42118698 1 citation (Europe PMC) Texte intégral en libre accèsSource : Europe PMC

  17. Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma: A Multicenter Real-World Experience

    Turkish journal of haematology : official journal of Turkish Society of Haematology, 2026

    DOI 10.4274/tjh.galenos.2026.35403 PMID 41883301 1 citation (Europe PMC) Texte intégral en libre accèsSource : Europe PMC

  18. Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone

    Blood, 2026

    DOI 10.1182/blood.2025030113 PMID 41060326 8 citations (Europe PMC) Texte intégral en libre accèsSource : Europe PMC

  19. Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma

    Blood cancer journal, 2026

    DOI 10.1038/s41408-026-01466-2 PMID 41881954 4 citations (Europe PMC) Texte intégral en libre accèsSource : Europe PMC

  20. Burden of Disease, Treatment Patterns, and Healthcare Resource Utilization in Multiple Myeloma in the Middle East and North Africa Region: A Targeted Literature Review

    Oncology and Therapy, 2026

    DOI 10.1007/s40487-026-00428-9 PMID 41886244 Texte intégral en libre accèsSource : OpenAlex

  21. P12 | SUBCUTANEOUS DARATUMUMAB (DARA) + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE WITH DARA + LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVE

    Haematologica, 2026

    DOI 10.3324/haematol.2026.s2.14037 Texte intégral en libre accèsSource : OpenAlex

  22. Response to the comment on “[11C]-Methionine PET/CT in evaluation of bone marrow infiltration and usage as a prognostic tool in multiple myeloma”

    Annals of Nuclear Medicine, 2026

    DOI 10.1007/s12149-026-02237-6 PMID 42183990 Source : OpenAlex

  23. Matching-adjusted indirect comparison (MAIC) for belantamab mafodotin (belamaf) with pomalidomide and dexamethasone (BPd) vs daratumumab with pomalidomide and dexamethasone (DPd) in relapsed/refractory multiple myeloma (RRMM).

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.e19574 Texte intégral en libre accèsSource : OpenAlex

  24. The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta‐Analysis of the European Myeloma Network ( EMN )

    American Journal of Hematology, 2026

    DOI 10.1002/ajh.70397 PMID 42315477 Texte intégral en libre accèsSource : OpenAlex

  25. MM-134: Durable Clinical Benefit of B-Cell Maturation Antigen–Directed Therapy With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: DREAMM-8 Long-Term Responder Analysis

    Clinical Lymphoma Myeloma & Leukemia, 2026

    DOI 10.1016/s2152-2650(26)02835-1 Source : OpenAlex

  26. POSTER: MM-338: Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma: Final Analysis of Transplant-Ineligible Patients in the Phase 3 CEPHEUS Study

    Clinical Lymphoma Myeloma & Leukemia, 2026

    DOI 10.1016/s2152-2650(26)01304-2 Source : OpenAlex

  27. MM-326: New IMS/IMWG Consensus Genomic Staging Risk Criteria by Next-Generation Sequencing: Analysis of Daratumumab Benefit in Both High- and Standard-Risk Patients in the PERSEUS/EMN017 Study

    Clinical Lymphoma Myeloma & Leukemia, 2026

    DOI 10.1016/s2152-2650(26)02859-4 Source : OpenAlex

  28. POSTER: MM-1135: Efficacy Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment Treated With at Least Two Prior Lines of Therapy in the DREAMM-7 Trial

    Clinical Lymphoma Myeloma & Leukemia, 2026

    DOI 10.1016/s2152-2650(26)01416-3 Source : OpenAlex

  29. MM-338: Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma: Final Analysis of Transplant-Ineligible Patients in the Phase 3 CEPHEUS Study

    Clinical Lymphoma Myeloma & Leukemia, 2026

    DOI 10.1016/s2152-2650(26)02861-2 Source : OpenAlex

  30. POSTER: MM-326: New IMS/IMWG Consensus Genomic Staging Risk Criteria by Next-Generation Sequencing: Analysis of Daratumumab Benefit in Both High- and Standard-Risk Patients in the PERSEUS/EMN017 Study

    Clinical Lymphoma Myeloma & Leukemia, 2026

    DOI 10.1016/s2152-2650(26)01303-0 Source : OpenAlex

  31. MM-1135: Efficacy Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment Treated With at Least Two Prior Lines of Therapy in the DREAMM-7 Trial

    Clinical Lymphoma Myeloma & Leukemia, 2026

    DOI 10.1016/s2152-2650(26)02991-5 Source : OpenAlex

  32. POSTER: MM-134: Durable Clinical Benefit of B-Cell Maturation Antigen–Directed Therapy With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: DREAMM‐8 Long‐Term Responder Analysis

    Clinical Lymphoma Myeloma & Leukemia, 2026

    DOI 10.1016/s2152-2650(26)01286-3 Source : OpenAlex

  33. Additional file 1 of T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis

    Figshare, 2026

    DOI 10.6084/m9.figshare.34212681 Texte intégral en libre accèsSource : OpenAlex

  34. Practical Guidance on the Clinical Management of Belantamab Mafodotin for Patients With Relapsed/Refractory Multiple Myeloma: Recommendations From the Middle East and North Africa Expert Panel

    Clinical Lymphoma Myeloma and Leukemia, 2025

    DOI 10.1016/j.clml.2025.05.019 PMID 40579284 3 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  35. Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials

    Blood Advances, 2025

    DOI 10.1182/bloodadvances.2025016949 PMID 40763276 15 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  36. Understanding quality of life under talquetamab: Learning to measure what matters

    Cancer, 2025

    DOI 10.1002/cncr.70072 PMID 40856195 Source : ORCID

  37. Familial Multiple Myeloma: Insights From Epidemiology and Underlying Germline Genetic Predisposition to the Clinic

    Clinical Lymphoma Myeloma and Leukemia, 2025

    DOI 10.1016/j.clml.2025.01.011 PMID 39947961 1 citation (Europe PMC) Source : ORCID

  38. Disease Characteristics and Treatment Outcomes of Myeloma Patients Under 50 Years of Age: An Analysis of the Balkan Myeloma Study Group

    Clinical Lymphoma Myeloma and Leukemia, 2025

    DOI 10.1016/j.clml.2024.12.017 PMID 39890518 Source : ORCID

  39. Belantamab, Pomalidomide, and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone in Refractory Multiple Myeloma: DREAMM-8 Outcomes

    British Journal of Haematology, 2025

    Source : ORCID

  40. Characterization and Management of Ocular Events in Patients Treated with Belamaf, Pomalidomide, and Dexamethasone: DREAMM-8

    British Journal of Haematology, 2025

    Source : ORCID

  41. Current Anti-Myeloma Chimeric Antigen Receptor-T Cells: Novel Targets and Methods

    Balkan Medical Journal, 2025

    DOI 10.4274/balkanmedj.galenos.2025.2025-4-25 PMID 40619794 2 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  42. DREAMM-8: Belantamab Mafodotin plus Pomalidomide plus Dexamethasone in Patients with RRMM and 1 Prior Line of Therapy Including Lenalidomide

    British Journal of Haematology, 2025

    Source : ORCID

  43. Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

    New England Journal of Medicine, 2025

    DOI 10.1056/nejmoa2409029 PMID 39652675 89 citations (Europe PMC) Source : ORCID

  44. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

    Nature Medicine, 2025

    DOI 10.1038/s41591-024-03485-7 PMID 39910273 135 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  45. EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma

    Nature Reviews Clinical Oncology, 2025

    DOI 10.1038/s41571-025-01041-x PMID 40624367 149 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  46. Efficacy and safety of daratumumab in intermediate/ of CENTAURUS

    Blood, 2025

    DOI 10.1182/blood.2024025897 PMID 39652826 20 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  47. Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions

    Expert Opinion on Investigational Drugs, 2025

    DOI 10.1080/13543784.2025.2532446 PMID 40657944 3 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  48. Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network

    The Lancet Haematology, 2025

    DOI 10.1016/s2352-3026(25)00117-6 PMID 40580975 12 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  49. Outcomes following different upfront stem cell transplantation strategies for multiple myeloma: a statistical perspective on behalf of the Chronic Malignancies Working Party of the EBMT

    Bone Marrow Transplantation, 2025

    DOI 10.1038/s41409-025-02675-2 PMID 40739129 3 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  50. Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial

    European Journal of Haematology, 2025

    DOI 10.1111/ejh.14365 PMID 39777934 8 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID